Bioactivation versus detoxication of the urothelial carcinogen aristolochic acid I by human cytochrome P450 1A1 and 1A2.

Exposure to aristolochic acid (AA) is associated with human nephropathy and urothelial cancer. Individual susceptibility to AA-induced disease likely reflects individual differences in enzymes that metabolize AA. Herein, we evaluated AAI metabolism by human cytochrome P450 (CYP) 1A1 and 1A2 in two CYP1A-humanized mouse lines that carry functional human CYP1A1 and CYP1A2 genes in the absence of the mouse Cyp1a1/1a2 orthologs. Human and mouse hepatic microsomes and human CYPs were also studied. Human CYP1A1 and 1A2 were found to be principally responsible for reductive activation of AAI to form AAI-DNA adducts and for oxidative detoxication to 8-hydroxyaristolochic acid (AAIa), both in the intact mouse and in microsomes. Overall, AAI-DNA adduct levels were higher in CYP1A-humanized mice relative to wild-type mice, indicating that expression of human CYP1A1 and 1A2 in mice leads to higher AAI bioactivation than in mice containing the mouse CYP1A1 and 1A2 orthologs. Furthermore, an exclusive role of human CYP1A1 and 1A2 in AAI oxidation to AAIa was observed in human liver microsomes under the aerobic (i.e., oxidative) conditions. Because CYP1A2 levels in human liver are at least 100-fold greater than those of CYP1A1 and there exists a > 60-fold genetic variation in CYP1A2 levels in human populations, the role of CYP1A2 in AAI metabolism is clinically relevant. The results suggest that, in addition to CYP1A1 and 1A2 expression levels, in vivo oxygen concentration in specific tissues might affect the balance between AAI nitroreduction and demethylation, which in turn would influence tissue-specific toxicity or carcinogenicity.

[1]  J. Hudeček,et al.  Human cytochromes P450 1A1 and 1A2 participate in detoxication of carcinogenic aristolochic acid. , 2008, Neuro endocrinology letters.

[2]  Dominic P. Williams,et al.  Development of a transactivator in hepatoma cells that allows expression of phase I, phase II, and chemical defense genes. , 2006, American journal of physiology. Cell physiology.

[3]  D. Nebert,et al.  Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. , 1989, Molecular endocrinology.

[4]  Kurt Straif,et al.  A review of human carcinogens--Part C: metals, arsenic, dusts, and fibres. , 2009, The Lancet. Oncology.

[5]  A. Grollman,et al.  Detoxification of aristolochic acid I by O‐demethylation: Less nephrotoxicity and genotoxicity of aristolochic acid Ia in rodents , 2009, International journal of cancer.

[6]  J. Hudeček,et al.  The Anticancer Drug Ellipticine Forms Covalent DNA Adducts, Mediated by Human Cytochromes P450, through Metabolism to 13-Hydroxyellipticine and Ellipticine N2-Oxide , 2004, Cancer Research.

[7]  D. Nebert,et al.  Generation of 'humanized' hCYP1A1_1A2_Cyp1a1/1a2(-/-) mouse line. , 2007, Biochemical and biophysical research communications.

[8]  V. Arlt,et al.  Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. , 2008, Mutation research.

[9]  F. Debellé,et al.  Aristolochic acid nephropathy: a worldwide problem. , 2008, Kidney international.

[10]  Marie Stiborová,et al.  Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:Cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid‐DNA adducts found in patients with urothelial cancer , 2005, International journal of cancer.

[11]  B. Sopko,et al.  Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase. , 2003, Carcinogenesis.

[12]  E. Frei,et al.  Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochromes P450 1A1 and 1A2. , 2001, Chemical research in toxicology.

[13]  EINZ,et al.  UROTHELIAL CARCINOMA ASSOCIATED WITH THE USE OF A CHINESE HERB ( ARISTOLOCHIA FANGCHI ) , 2022 .

[14]  B. Sopko,et al.  The binding of aristolochic acid I to the active site of human cytochromes P450 1A1 and 1A2 explains their potential to reductively activate this human carcinogen. , 2005, Cancer letters.

[15]  V. Arlt,et al.  Role of P450 1A1 and P450 1A2 in bioactivation versus detoxication of the renal carcinogen aristolochic acid I: studies in Cyp1a1-/-, Cyp1a2-/-, and Cyp1a1/1a2-/- mice. , 2011, Chemical research in toxicology.

[16]  Graham M Lord,et al.  Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. , 2009, Carcinogenesis.

[17]  M. Jadoul,et al.  Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs , 1993, The Lancet.

[18]  V. Arlt,et al.  Chemical and molecular basis of the carcinogenicity of Aristolochia plants. , 2009, Current opinion in drug discovery & development.

[19]  Hui Wang,et al.  Induction of P450 1A by 3-methylcholanthrene protects mice from aristolochic acid-I-induced acute renal injury. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  F. Gonzalez,et al.  Human cDNA‐Expressed Cytochrome P450 IA2: Mutagen Activation and Substrate Specificity , 1989, Molecular carcinogenesis.

[21]  Slobodan Petar Rendic,et al.  Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.

[22]  Amanda Smith,et al.  Cytochrome P450 1A2 Detoxicates Aristolochic Acid in the Mouse , 2010, Drug Metabolism and Disposition.

[23]  D. Toncheva,et al.  Identification of NQO1 and GSTs genotype frequencies in Bulgarian patients with Balkan endemic nephropathy. , 2004, Journal of nephrology.

[24]  D. Nebert.  Comparison of gene expression in cell culture to that in the intact animal: relevance to drugs and environmental toxicants. Focus on "development of a transactivator in hepatoma cells that allows expression of phase I, phase II, and chemical defense genes". , 2006, American journal of physiology. Cell physiology.

[25]  V. Arlt,et al.  The human carcinogen aristolochic acid i is activated to form DNA adducts by human NAD(P)H:quinone oxidoreductase without the contribution of acetyltransferases or sulfotransferases , 2011, Environmental and molecular mutagenesis.

[26]  C. van Ypersele de Strihou,et al.  Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. , 1996, Cancer research.

[27]  Guowang Xu,et al.  Study of the phase I and phase II metabolism of nephrotoxin aristolochic acid by liquid chromatography/tandem mass spectrometry. , 2006, Rapid communications in mass spectrometry : RCM.

[28]  D. Nebert,et al.  Differential metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in mice humanized for CYP1A1 and CYP1A2. , 2005, Chemical research in toxicology.

[29]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[30]  R. Turesky.  Interspecies metabolism of heterocyclic aromatic amines and the uncertainties in extrapolation of animal toxicity data for human risk assessment. , 2005, Molecular nutrition & food research.

[31]  Václav Martínek,et al.  Expression of cytochrome P450 1A1 and its contribution to oxidation of a potential human carcinogen 1-phenylazo-2-naphthol (Sudan I) in human livers. , 2005, Cancer letters.

[32]  Marie Stiborová,et al.  Sudan I is a potential carcinogen for humans: evidence for its metabolic activation and detoxication by human recombinant cytochrome P450 1A1 and liver microsomes. , 2002, Cancer research.

[33]  D. Nebert,et al.  Generation of a 'humanized' hCYP1A1_1A2_Cyp1a1/1a2(-/-)_Ahrd mouse line harboring the poor-affinity aryl hydrocarbon receptor. , 2008, Biochemical and biophysical research communications.

[34]  V. Arlt,et al.  The 32P-postlabeling assay for DNA adducts , 2007, Nature Protocols.

[35]  V. Arlt,et al.  Is aristolochic acid a risk factor for Balkan endemic nephropathy‐associated urothelial cancer? , 2002, International journal of cancer.

[36]  M. Nangaku,et al.  The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease , 2010, Nature Reviews Nephrology.

[37]  B. Jelaković,et al.  Aristolochic acid and the etiology of endemic (Balkan) nephropathy , 2007, Proceedings of the National Academy of Sciences.

[38]  K. Straif,et al.  A review of human carcinogens--Part A: pharmaceuticals. , 2009, The Lancet. Oncology.

[39]  D. Toncheva,et al.  Genetic polymorphisms of cytochrome P450 among patients with Balkan endemic nephropathy (BEN). , 2005, Clinical biochemistry.

[40]  V. Arlt,et al.  Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[41]  Graham M Lord,et al.  Gene expression changes induced by the human carcinogen aristolochic acid I in renal and hepatic tissue of mice , 2011, International journal of cancer.

[42]  C. Decaestecker,et al.  Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.